FDA Clears Replimune Melanoma Drug as Medicare Tweaks Pricing Timeline

By Ed Silverman · STAT News · 2026-08-07

STAT News reports that the FDA granted accelerated approval to Replimune’s melanoma treatment, Tudriqev, despite previous trial design concerns raised by agency staff. Separately, a quiet adjustment to Medicare’s drug negotiation criteria has delayed price discussions for a high-

STAT News reports that the FDA granted accelerated approval to Replimune’s melanoma treatment, Tudriqev, despite previous trial design concerns raised by agency staff. Separately, a quiet adjustment to Medicare’s drug negotiation criteria has delayed price discussions for a high-